View Single Post
Old 12-04-2013, 11:35 AM   #3
donocco
Senior Member
 
Join Date: Oct 2013
Posts: 474
Re: Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Elizabeth

You've given me a lot of material
to study. I think LEE011 is also Novartis. It works like
Palbociclib as a CDK/4,6 inhibitor. I did some research
on it. The dose will probably be 600mg daily and the side effects are anemia, thrombocytopenia, lymphopenia, decreased appetite, fatigue, nausea, vomiting, diarrhea, decreased albumin concentration,
and possible increased blood sugar. Despite this list of
side effects it is considered a relatively safe drug and
may be an immediate rival to Palbociclib which, I think will be FDa approved
in a few years or earlier.

Paul
donocco is offline   Reply With Quote